

# BC Cancer Protocol Summary for Palliative Therapy for Advanced Adrenal Cortical Cancer Using DOXOrubicin

**Protocol Code**

**GUAVD**

**Tumour Group**

**Genitourinary**

**Contact Physician**

**Dr. Kim Chi**

## ELIGIBILITY:

- Advanced adrenal cortical cancer resistant to Mitotane (GUMITO)

## EXCLUSIONS:

- Contraindication to DOXOrubicin

## TESTS:

- Baseline: CBC and diff, [ALT](#), GGT, LDH, bilirubin, assessment of tumour size
- Before each treatment: CBC and diff
- If clinically indicated: bilirubin, [GGT](#), [ALT](#), [LDH](#)

## PREMEDICATIONS:

- Antiemetic protocol for moderate emetogenic chemotherapy protocols (see [SCNAUSEA](#))

## TREATMENT:

<b>Drug</b>	<b>Dose</b>	<b>BC Cancer Administration Guideline</b>
DOXOrubicin	60 mg/m <sup>2</sup>	IV push

Repeat every 21 days x 2 – 3 cycles, then re-assess for response  
Discontinue if no response.

## DOSE MODIFICATIONS:

### 1. Hematological:

<b>ANC (x10<sup>9</sup>/L)</b>		<b>Platelets (x10<sup>9</sup>/L)</b>	<b>Dose (all drugs)</b>
greater than 1.5	and	greater than 100	100%
1.0 to 1.5	or	70 to 100	75%
less than 1.0	or	less than 70	delay

2. **Hepatic dysfunction:** Dose modification required for DOXOrubicin. Refer to [BC Cancer Drug Manual](#).
3. **Neutropenic fever:** Reduce dose by 25% if treated for neutropenic sepsis.

#### **PRECAUTIONS:**

1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
2. **Extravasation:** DOXOrubicin causes pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines.
3. **Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution, if at all, in patients with severe hypertension or cardiac dysfunction. Cardiac assessment recommended if lifelong dose of 450 mg/m<sup>2</sup> to be exceeded. Refer to [BC Cancer Drug Manual](#).
4. **Mucositis:** Severe mucositis may occur especially in patients previously radiated in the head and neck regions.

**Call Dr. Kim Chi at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**

#### **References:**